Ocular Therapeutix makes slides with SOL-1 Phase 3 results for AXPAXLI in wet AMD available at Macula Society

OCULAR THERAPEUTIX, INC

Slides from 49th Macula Society Annual Meeting on Feb 27, 2026 posted on investor website.
Presentation covers detailed results from SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI).
AXPAXLI is being developed for treatment of wet age-related macular degeneration (wet AMD).
Filing does not disclose the actual trial outcomes or numerical results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.